Neoplasm.News

IDH inhibitor × Myeloid × Clear all

6 Announcements

FDA approves ivosidenib for myelodysplastic syndromes

Drug: Tibsovo (ivosidenib) · IDH inhibitor
Condition: Myeloid

FDA approves olutasidenib for relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation

Drug: Rezlidhia (olutasidenib) · IDH inhibitor
Conditions: MyeloidOther hematologic neoplasm

FDA approves ivosidenib in combination with azacitidine for newly diagnosed acute myeloid leukemia

Trial: AGILE
Drug: Tibsovo (ivosidenib) · IDH inhibitor
Conditions: MyeloidOther hematologic neoplasm

FDA approves ivosidenib as first-line treatment for AML with IDH1 mutation

Drug: TIBSOVO (ivosidenib) · IDH inhibitor
Condition: Myeloid

FDA approves ivosidenib for relapsed or refractory acute myeloid leukemia

Drug: Tibsovo (ivosidenib) · IDH inhibitor
Conditions: MyeloidOther hematologic neoplasm

FDA granted regular approval to enasidenib for the treatment of relapsed or refractory AML

Drug: IDHIFA (enasidenib) · IDH inhibitor
Condition: Myeloid